These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25388322)

  • 1. ["Before and after CML": illness experiences and dimensions of chronic myeloid leukemia as a biographical disruption].
    López YA; Trad LA
    Cad Saude Publica; 2014 Oct; 30(10):2199-208. PubMed ID: 25388322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms.
    Moulin SM; Eutrópio FJ; Souza JO; Busato FO; Olivieri DN; Tadokoro CE
    Support Care Cancer; 2017 Mar; 25(3):951-955. PubMed ID: 27866336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
    Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
    J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in chronic myeloid leukemia.
    Trask PC; Cella D; Powell C; Reisman A; Whiteley J; Kelly V
    Leuk Res; 2013 Jan; 37(1):9-13. PubMed ID: 23116602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
    Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M
    Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporally divergent significant meanings, biographical disruption and self-management for chronic joint pain.
    Morden A; Jinks C; Ong BN
    Health (London); 2017 Jul; 21(4):357-374. PubMed ID: 26293290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Embodiment and the foundation of biographical disruption.
    Engman A
    Soc Sci Med; 2019 Mar; 225():120-127. PubMed ID: 30825759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.
    Efficace F; Breccia M; Cottone F; Okumura I; Doro M; Riccardi F; Rosti G; Baccarani M
    Support Care Cancer; 2016 Dec; 24(12):4887-4894. PubMed ID: 27448405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia.
    Chikkodi SV; Malhotra P; Naseem S; Khadwal A; Prakash G; Sahu KK; Kumari S; Suri V; Varma N; Varma S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S114-9. PubMed ID: 26297263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ménière's disease and biographical disruption: Where family transitions collide.
    Bell SL; Tyrrell J; Phoenix C
    Soc Sci Med; 2016 Oct; 166():177-185. PubMed ID: 27566047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of symptom burden on patient quality of life in chronic myeloid leukemia.
    Cella D; Nowinski CJ; Frankfurt O
    Oncology; 2014; 87(3):133-47. PubMed ID: 25012261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient perceptions of treatment-free remission in chronic myeloid leukemia.
    Villemagne Sanchez LA; O'Callaghan C; Gough K; Hall K; Kashima Y; Seymour JF; Schofield P; Ross DM
    Leuk Lymphoma; 2018 Feb; 59(2):406-415. PubMed ID: 28617066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
    Peng C; Li S
    Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia].
    González FA; Villegas A; Ferro MT; San Román C; Sáez I; López M; del Potro E; Alvarez A; Martínez R; Díaz Madiavilla J
    Med Clin (Barc); 1993 Oct; 101(14):521-4. PubMed ID: 8231395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
    Lam MS; Cheung N
    J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.